

Requested by JOINT COMMITTEE ON MARIJUANA REGULATION

**PROPOSED AMENDMENTS TO
SENATE BILL 1057**

1 On page 1 of the printed bill, line 9, after the semicolon insert “repealing
2 ORS 475B.520;”.

3 On page 15, after line 39, insert:
4

5 **“TRACKING**

6
7 **“SECTION 36c. Section 36d of this 2017 Act is added to and made a
8 part of ORS 475B.400 to 475B.525.**

9 **“SECTION 36d. (1) The Oregon Health Authority shall enter into
10 an agreement with the Oregon Liquor Control Commission under
11 which the commission shall use the system developed and maintained
12 under ORS 475B.150 to track:**

13 **“(a) The propagation of immature marijuana plants and the pro-
14 duction of marijuana by persons designated to produce marijuana by
15 registry identification cardholders;**

16 **“(b) The processing of marijuana into medical cannabinoid pro-
17 ducts, cannabinoid concentrates and cannabinoid extracts that are
18 transferred to a medical marijuana dispensary;**

19 **“(c) The transfer of usable marijuana, immature marijuana plants,
20 medical cannabinoid products, cannabinoid concentrates and
21 cannabinoid extracts by a medical marijuana dispensary to a registry**

1 identification cardholder or the designated primary caregiver of a
2 registry identification cardholder; and

3 “(d) The transfer of usable marijuana, immature marijuana plants,
4 medical cannabinoid products, cannabinoid concentrates and
5 cannabinoid extracts between marijuana grow sites, marijuana pro-
6 cessing sites and medical marijuana dispensaries.

7 “(2) Marijuana grow sites, marijuana processing sites, medical
8 marijuana dispensaries and any other person that processes marijuana
9 into medical cannabinoid products and cannabinoid concentrates for
10 the purpose of transferring the medical cannabinoid products and
11 cannabinoid concentrates to a medical marijuana dispensary are sub-
12 ject to tracking under this section. The commission shall adopt by
13 rule a schedule by which the commission shall subject marijuana grow
14 sites, marijuana processing sites and medical marijuana dispensaries
15 to tracking under this section.

16 “(3) On and after the date on which a marijuana grow site becomes
17 subject to tracking under this section, the marijuana grow site is ex-
18 empt from the requirements of ORS 475B.423 and the provisions of
19 ORS 475B.420 that relate to ORS 475B.423.

20 “(4) On and after the date on which a marijuana processing site
21 becomes subject to tracking under this section, the marijuana pro-
22 cessing site is exempt from the requirements of ORS 475B.438 and the
23 provisions of ORS 475B.435 that relate to ORS 475B.438.

24 “(5) On and after the date on which a medical marijuana dispensary
25 becomes subject to tracking under this section, the medical marijuana
26 dispensary is exempt from the requirements of ORS 475B.453 and the
27 provisions of ORS 475B.450 that relate to ORS 475B.453.

28

29

“OREGON CANNABIS COMMITTEE

30

1 **“SECTION 36e. Section 36f of this 2017 Act is added to and made a**
2 **part of ORS 475B.400 to 475B.525.**

3 **“SECTION 36f. (1) The Oregon Cannabis Committee is established**
4 **within the Oregon Health Authority.**

5 **“(2) The committee consists of the following nine members ap-**
6 **pointed by the Governor:**

7 **“(a) One registry identification cardholder from each of the follow-**
8 **ing regions of the state:**

9 **“(A) The northeast part of this state;**

10 **“(B) The southeast part of this state;**

11 **“(C) The northwest part of this state; and**

12 **“(D) The southwest part of this state;**

13 **“(b) An attending physician who has diagnosed a person as having**
14 **a debilitating medical condition for which the medical use of**
15 **marijuana may mitigate the symptoms or effects;**

16 **“(c) A person who holds a marijuana grow site registration card**
17 **under ORS 475B.420;**

18 **“(d) A designated primary caregiver;**

19 **“(e) A medical marijuana dispensary owner; and**

20 **“(f) A person certified under ORS 475B.235 to conduct research.**

21 **“(3) The committee shall:**

22 **“(a) Serve as a coordinating body between the Oregon Health Au-**
23 **thority and the Oregon Liquor Control Commission on the adminis-**
24 **tration of ORS 475B.010 to 475B.395 and 475B.400 to 475B.525 with**
25 **respect to registry identification cardholders and designated primary**
26 **caregivers;**

27 **“(b) Identify and evaluate potential factors that could prevent a**
28 **registry identification cardholder from accessing usable marijuana,**
29 **medical cannabinoid products, cannabinoid concentrates and**
30 **cannabinoid extracts for medical use;**

1 **“(c) Make recommendations to the authority on the implementation**
2 **of processes and regulations that would ensure that registry identifi-**
3 **cation cardholders have access to usable marijuana, medical**
4 **cannabinoid products, cannabinoid concentrates and cannabinoid ex-**
5 **tracts for medical use;**

6 **“(d) Make recommendations to the authority on the public and**
7 **private research of the medical properties of cannabis and how to fa-**
8 **cilitate the public and private research of cannabis;**

9 **“(e) Compile information regarding:**

10 **“(A) The availability of different strains of usable marijuana and**
11 **different types of medical cannabinoid products, cannabinoid concen-**
12 **trates and cannabinoid extracts;**

13 **“(B) The levels of tetrahydrocannabinol present in different strains**
14 **of usable marijuana and different types of medical cannabinoid pro-**
15 **ducts, cannabinoid concentrates and cannabinoid extracts;**

16 **“(C) Whether those levels of tetrahydrocannabinol are intoxicating**
17 **and the availability of strains of usable marijuana and types of medical**
18 **cannabinoid products, cannabinoid concentrates and cannabinoid ex-**
19 **tracts that are not intoxicating;**

20 **“(D) For each type of debilitating medical condition, the strains of**
21 **usable marijuana and the types of medical cannabinoid products,**
22 **cannabinoid concentrates and cannabinoid extracts that most effec-**
23 **tively treat that debilitating medical condition;**

24 **“(E) For selected medical conditions that are not debilitating med-**
25 **ical conditions, the strains of usable marijuana and the types of med-**
26 **ical cannabinoid products, cannabinoid concentrates and cannabinoid**
27 **extracts that most effectively treat that medical condition; and**

28 **“(F) Those medical conditions that are not debilitating medical**
29 **conditions that should be included as debilitating medical conditions,**
30 **and whether the inclusion of the conditions should be by administra-**

1 **tive or legislative action; and**

2 **“(f) Monitor and study federal laws and regulations regarding**
3 **marijuana, the administration of those laws and regulations by the**
4 **federal government and the impact of that administration on ORS**
5 **475B.400 to 475B.525.**

6 **“(4) A majority of the members of the committee constitutes a**
7 **quorum for the transaction of business.**

8 **“(5) Official action by the committee requires the approval of a**
9 **majority of the members of the committee.**

10 **“(6) The committee shall elect one of its members to serve as**
11 **chairperson.**

12 **“(7) The committee shall meet at times and places specified by the**
13 **call of the chairperson or of a majority of the members of the com-**
14 **mittee.**

15 **“(8) The term of office of each member of the committee is four**
16 **years, but a member serves at the pleasure of the Governor. Before**
17 **the expiration of the term of a member, the Governor shall appoint a**
18 **successor whose term begins July 1 next following. A member is eli-**
19 **gible for reappointment, but may not serve consecutive terms. If there**
20 **is a vacancy for any cause, the Governor shall make an appointment**
21 **to become immediately effective for the unexpired term.**

22 **“(9) Members of the committee are not entitled to compensation,**
23 **but may be reimbursed for actual and necessary travel and other ex-**
24 **penses incurred by them in the performance of their official duties in**
25 **the manner and amounts provided for in ORS 292.495. Claims for ex-**
26 **penses shall be paid out of funds appropriated to the authority for**
27 **purposes of the committee.**

28 **“SECTION 36g. Notwithstanding the term of office specified by**
29 **section 36f of this 2017 Act, of the members first appointed to the**
30 **Oregon Cannabis Committee:**

